Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results

Rhea-AI Summary

Clarus Therapeutics Holdings (Nasdaq: CRXT) announced it will release its Q1 2022 financial results on May 16, 2022, after market close. A conference call is scheduled for the same day at 5:15 p.m. ET, where investors can discuss the results. Domestic callers can dial (844) 249-2007 and international callers can use (224) 619-3902, using conference ID 7677008. Clarus specializes in androgen and metabolic therapies, with its first product being JATENZO® (testosterone undecanoate). More details can be found on their investor website.

NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its first quarter 2022 financial and operating results on Monday, May 16, 2022, after the market closes.

Clarus will host a conference call on Monday, May 16, 2022, at 5:15 p.m. ET to discuss the results. The dial-in numbers are (844) 249-2007 for domestic callers and (224) 619-3902 for international callers. The conference ID number is 7677008. A live webcast and replay of the conference call will be accessible through the Investors section of Clarus Therapeutics’ website at Investors.ClarusTherapeutics.com.

About Clarus Therapeutics Holdings, Inc.
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women – including potential therapies for orphan indications. Clarus Therapeutics’ first commercial product is JATENZO® (testosterone undecanoate). For more information, visit www.clarustherapeutics.com and www.jatenzo.com. Follow us on Twitter (@Clarus_Thera) and LinkedIn (Clarus Therapeutics).

JATENZO® is a registered trademark of Clarus Therapeutics Holdings, Inc.

Clarus Investor Relations Contact:

Kara Stancell
Vice President, Investor Relations & Corporate Communications
kstancell@clarustherapeutics.com
(847) 562-4300 x 206

FAQ

When will Clarus Therapeutics release its Q1 2022 financial results?

Clarus Therapeutics will release its Q1 2022 financial results on May 16, 2022, after market close.

What time is the Clarus Therapeutics Q1 2022 conference call?

The conference call for Clarus Therapeutics Q1 2022 results is scheduled for May 16, 2022, at 5:15 p.m. ET.

What is the conference ID for the Clarus Therapeutics call?

The conference ID for the Clarus Therapeutics call is 7677008.

How can I access the Clarus Therapeutics conference call?

The Clarus Therapeutics conference call can be accessed by calling (844) 249-2007 for domestic callers or (224) 619-3902 for international callers.

What is JATENZO® from Clarus Therapeutics?

JATENZO® is the first commercial product developed by Clarus Therapeutics, which contains testosterone undecanoate.